πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 308 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12233090

Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19

The Regents of the University of California Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234295

Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytok

AUTOLUS LIMITED Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226435

Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19

The Regents of the University of California Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221462

Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

Allogene Therapeutics, Inc. Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215347

Chimeric antigen receptors with enhanced signaling and activities and uses thereof

Allogene Therapeutics, Inc. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12202902

FLT3-specific chimeric antigen receptors and methods using same

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186375

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186363

Compositions and methods for dengue virus chimeric constructions in vaccines

The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180484

Chimeric antigen receptors targeting B-cell maturation antigen

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161672

Chimeric antigen receptor and methods of use thereof

The Regents of the University of California Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161696

Methods of treating hemophilic arthropathy using chimeric clotting factors

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12163169

Inducible chimeric cytokine receptors

Allogene Therapeutics, Inc. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12150959

Chimeric antigen receptors with BCMA specificity and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139522

T-cells comprising two different chimeric antigen receptors and uses thereof

THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12122846

Chimeric antigen receptor for tumor targeting

Fate Therapeutics, Inc. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121542

BCMA chimeric antigen receptor based on single domain antibody and use thereof

SHENZHEN PREGENE BIOPHARMA CO., LTD. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084514

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084497

SIRP1Ξ± targeted chimeric proteins and uses thereof

Orionis Biosciences, Inc Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12077785

Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modu

SOTIO BIOTECH INC. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12071632

Chimeric vectors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065498

Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses

Cell Design Labs, Inc. Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065490

Chimeric antigen receptors and methods of making

The Board of Regents of the University of Texas System Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065479

Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof

The Regents of the University of California Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted